QuidelOrtho Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian J. Blaser
- Full Time Employees
- 6,500
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 9975 Summers Ridge Road San Diego CA United States 92121
- IPO Date
- Feb 1, 1991
- CIK
- 0001906324
- Website
- quidelortho.com
- Similar Companies
- Business
- QuidelOrtho Corporation (Nasdaq: QDEL), founded in 1979 and headquartered in San Diego, California, develops, manufactures and markets in vitro diagnostic technologies for point-of-care settings, clinical laboratories and transfusion medicine worldwide, serving customers in over 140 countries across North America, Europe, the Middle East, Africa, China and other regions. The company offers a comprehensive portfolio of products and services including visually-read lateral flow assays such as QuickVue for infectious diseases, reproductive health and cardiac markers; Sofia fluorescent immunoassay analyzers and tests; direct fluorescent antibody tests; molecular diagnostics via LYRA real-time PCR assays and the forthcoming LEX Diagnostics platform; clinical chemistry and immunodiagnostic systems like VITROS; donor screening with Ortho Summit, VERSEIA and VITROS systems; pre-transfusion testing through ORTHO VISION analyzers and ORTHO CONNECT software; semi-automated immunohematology solutions including ORTHO Workstation and ORTHO OPTIX Reader; and Ortho Care services and informatics for lab efficiency. In recent developments, QuidelOrtho announced in June 2025 a strategy to accelerate growth in point-of-care molecular diagnostics by intending to acquire full ownership of LEX Diagnostics for approximately $100 million upon U.S. FDA clearance expected in late 2025 or early 2026, while discontinuing development of its Savanna platform; the company also completed a major debt refinancing in August 2025, issuing $1.15 billion in 5-year Term Loan A, $1.45 billion in 7-year Term Loan B, a $100 million delayed draw facility and a $700 million revolving credit facility to extend maturities, reduce amortization and enhance financial flexibility.
Company News
QuidelOrtho Corporation (QDEL) Q3 2026 Earnings Call Transcript
What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call
QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates
QuidelOrtho Reports Third Quarter 2026 Financial Results
Transforming Data Into Actionable Insights in the Lab
QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)
QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now
Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
Contrasting QuidelOrtho (NASDAQ:QDEL) & Cooper Companies (NASDAQ:COO)
Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
85,251 Shares in QuidelOrtho Corporation $QDEL Purchased by Squarepoint Ops LLC
Faster Answers, Better Decisions: ADLM 2026 Highlights
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho (NASDAQ:QDEL) Shares Gap Down – Time to Sell?